Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The company plans to raise US $ 15 million
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Final decision from the European Commission is anticipated within the coming months
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Subscribe To Our Newsletter & Stay Updated
